Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.…
Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates
Seres Therapeutics (NASDAQ: MCRB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 66 employees.
The shares were at 1.240 USD on 20 November 2026, down 91.2% over 52 weeks. Its 52-week range is 1.201 USD to 29.98 USD: the price is 95.9% below the high and 3.2% above the low.
Its market capitalisation is 12.64M USD.
Seres Therapeutics reports return on equity of 12.9% and revenue up 68.9% year over year.
Its debt exceeds its cash by 18.24M USD, a debt-to-equity ratio of 1.88. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 11 March 2027.